
Understand the clinical process for testosterone testing, from symptoms and morning sampling to repeat results, SHBG and free testosterone.

A structured testosterone evaluation helps distinguish a persistent low result from an isolated reading and clarifies how that finding fits changes in libido or physical function.
This article is for informational purposes only and is not medical advice. A qualified clinician should interpret individual symptoms and results and make decisions about further testing or treatment.
Collection conditions are part of the assessment. The European Association of Urology (EAU) guideline recommends measuring total testosterone in the morning between 07:00 and 10:00 while fasting.
The guideline identifies several points for the clinician and laboratory to address before collection:
The guideline cites research in which non-fasting measurements underestimated total testosterone by more than 30%. That finding supports attention to collection conditions. It is not a formula for adjusting an individual result.
Before an appointment, patients can ask the ordering clinician or laboratory how these requirements apply to the planned collection. The recommendations describe appropriate testing conditions rather than a universal preparation schedule for every patient.
The EAU guideline page was updated in 2026. Its approach combines clinical assessment with laboratory confirmation. The following sequence describes that evaluation rather than a self-testing plan.
The starting point is a description of the concern: reduced desire, erection changes, lower energy or reduced physical function. These concerns should remain distinct rather than being grouped under a general label such as “poor performance.”
The EAU lists reduced libido and erectile dysfunction among the more-specific symptoms of hypogonadism. Fewer spontaneous or morning erections also belong to that group. Reduced energy and physical strength or function are less specific.
Being able to describe sexual changes more precisely gives the consultation a clearer focus. It also keeps a laboratory number connected to the concern that prompted testing.
The clinician considers illnesses and medicines that may affect testosterone. The EAU also identifies obesity and other comorbidities as important factors associated with functional hypogonadism.
This review is more than background information. It helps structure the investigation of possible causes. The guideline describes functional hypogonadism as a diagnosis of exclusion after organic causes have been considered.
For the patient, the useful contribution is an accurate account of relevant health conditions and medicines. The clinician decides how those details affect the evaluation.
Total testosterone is measured under the planned collection conditions. The clinician then reviews the measured value alongside the time of collection and fasting status.
At this stage, the task is to establish a laboratory finding that can be assessed in context. A result should stay connected to the circumstances in which it was obtained rather than being separated from them when it is later discussed or compared.
The EAU recommends repeating a low total-testosterone result on at least two separate occasions before testosterone therapy is started. This addresses whether the low finding is consistent.
The clinician reviews the measurements together with their collection conditions. Repeat testing is therefore part of the diagnostic evaluation rather than simply another opportunity to compare a number with a reference range.
A discussion of the questions raised by an initial low reading can help patients prepare for this stage of follow-up.
The EAU says free testosterone may help refine assessment when total testosterone is near the lower limit. It also recommends SHBG measurement and free-testosterone calculation in conditions associated with altered SHBG.
SHBG stands for sex hormone-binding globulin. According to the guideline, SHBG may be higher with ageing or hyperthyroidism. It may be lower with obesity or hypothyroidism. Insulin resistance and some medicines can also affect SHBG.
These are reasons for a clinician to consider additional measurements in selected cases. Free-testosterone testing is not presented as a required addition for every man.
The clinician considers symptoms together with the repeated testosterone results and any additional biomarkers. The EAU's diagnostic approach requires compatible symptoms or signs alongside consistently low testosterone.
This final review asks how the findings fit the reported change in sexual or physical function. When the pieces do not align, the discussion returns to other possible contributors identified through the medical assessment rather than assuming that testosterone explains the whole concern.
The laboratory output is numerical. The clinical interpretation is broader. A total-testosterone value is considered alongside the laboratory's reference range. SHBG and free-testosterone findings add information when those tests have been ordered.
The physician's review also includes the circumstances of collection and the symptoms being investigated. These parts of the assessment answer different questions and should be considered together.
The EAU identifies 12 nmol/L (3.5 ng/mL) as a threshold in its late-onset hypogonadism guidance. It says that threshold should be integrated with the patient's symptoms and clinical profile.
A reference range provides laboratory context. It does not independently explain a change in libido or physical function. Likewise, the EAU's threshold is not a universal answer detached from the patient or the measurement method.
The central limitation belongs here: symptoms are not exclusive to hypogonadism, and neither a symptom nor one laboratory value establishes the diagnosis. Even the more-specific sexual symptoms require biochemical and clinical assessment.
The practical question for the physician is how the measured results fit the clinical picture, including whether low findings have been confirmed under appropriate conditions.
A free-testosterone result needs a method attached to its interpretation. The EAU describes equilibrium dialysis as the most accurate method for measuring free testosterone.
The guideline also describes calculation from total testosterone, SHBG and albumin as an alternative. A calculated result and a directly measured result should therefore be understood in terms of how each was produced.
The EAU notes variability in laboratory methods and pre-analytic practices. It advises close collaboration between clinicians and laboratories to support accurate and comparable measurements.
For patients trying to understand how the related hormone measurements fit together, a useful question is whether free testosterone was measured or calculated. The treating clinician can explain why that method was used and what information it adds.
The report should be reviewed against the specific concern that prompted testing. A consultation about reduced desire needs to address desire. A consultation about erection changes should retain that distinction. Reduced energy or physical strength also needs its own clinical context.
The EAU's distinction between symptom groups helps physicians structure that review. It does not turn a testosterone value into a score for sexual function or physical performance.
When symptoms and results do not line up, the guideline supports considering medicines and other illnesses. The responsible response is a broader clinical discussion rather than forcing the laboratory result to provide a single explanation.
Once results are available, bring them to the clinician overseeing the evaluation. Include the collection time and fasting status in that discussion. Mention any illness around testing and clarify the sexual or physical change that remains a concern.
Three questions can help focus the appointment:
The next step is a clinician-led interpretation of the full assessment. Treatment decisions should follow that review rather than the laboratory number alone.
Hormone testing for sexual or physical changes is led by a qualified clinician, with Testostra helping men understand the evidence behind the measurements. Its reporting explains why total testosterone, free testosterone and SHBG need context so readers can bring better-informed questions to the consultation rather than treating numbers as a personal diagnosis.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra